Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-624-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.50 million
Profitability
Miscellaneous
Employees130
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics, Inc. (NASDAQ:CYTK) released its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company had revenue of $7.14 million for the quarter, compared to analyst estimates of $6.81 million. Cytokinetics had a negative return on equity of 575.21% and a negative net margin of 308.73%. View Cytokinetics' Earnings History.
When is Cytokinetics' next earnings date?
What price target have analysts set for CYTK?
6 brokers have issued 1 year price objectives for Cytokinetics' stock. Their forecasts range from $16.00 to $26.00. On average, they anticipate Cytokinetics' stock price to reach $20.17 in the next year. This suggests a possible upside of 75.1% from the stock's current price. View Analyst Price Targets for Cytokinetics.
What is the consensus analysts' recommendation for Cytokinetics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.
Has Cytokinetics been receiving favorable news coverage?
Media stories about CYTK stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cytokinetics earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Cytokinetics.
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include Myokardia (MYOK), Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Cambrex (CBM), Portola Pharmaceuticals (PTLA), Agios Pharmaceuticals (AGIO) and Zogenix (ZGNX).
What other stocks do shareholders of Cytokinetics own?
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
- Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
- Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
- Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
- Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)
Who are Cytokinetics' major shareholders?
Cytokinetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Rhumbline Advisers (0.28%), Assenagon Asset Management S.A. (0.10%), State of Alaska Department of Revenue (0.08%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Cytokinetics stock include Caryn Gordon Mcdowell, Fady Ibraham Malik and Robert I Blum. View Institutional Ownership Trends for Cytokinetics.
Which institutional investors are selling Cytokinetics stock?
CYTK stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.
Which institutional investors are buying Cytokinetics stock?
CYTK stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of Alaska Department of Revenue, Rhumbline Advisers and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Cytokinetics.
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $11.52.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $675.98 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.
What is Cytokinetics' official website?
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
